课题基金 / 基金详情

Apolipoproteins and the complications of Type 1 diabetes

Apolipoproteins and the complications of Type 1 diabetes
载脂蛋白和 1 型糖尿病的并发症
批准号:
6861662
负责人:
TIMOTHY J LYONS
金额:
$31.02万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-09-30 至 2006-08-31

项目摘要

项目成果

TIMOTHY J LYONS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Objectives: Determine cross-sectional and prospective associations of apolipoprotein-based plasma lipoprotein subclasses to vascular complications of Type 1 diabetes (retinopathy, nephropathy, carotid intimal thickening) using DCCT/EDIC samples. To define responses to lipid-lowering and insulin sensitizing drugs. To develop clinically applicable assays to predict complication risk and response to treatment. Rationale: Dyslipidemia (quantitative and qualitative) is implicated in micro- and macro-vascular complications of Type 1 diabetes. Although apolipoprotein-based lipoprotein subclass levels are implicated in vascular disease in non-diabetic and Type 2 diabetic populations, they have never been studied in Type 1 subjects, nor related to complication status or to other lipoprotein characteristics. Responses of apolipoprotein-defined subclasses to potential treatments in Type 1 diabetic subjects are unknown. Hypotheses: Apolipoprotein-based plasma lipoprotein subclass profiles are associated with, and may determine susceptibility to, vascular complications of Type 1 diabetes. Research Plan: First (R21) phase: determine apolipoprotein subclass profiles in 100 complication-prone and 100 complication-resistant DCCT/EDIC subjects; define associations with each of the three complications, select subclasses of interest for clinical assay development. Second (R33) phase: in locally-recruited Type 1 patients, intervene with atorvastatin, fenofibrate, Niaspan, and rosiglitazone and define effects. Develop clinically applicable assays. Methods: Stored samples from DCCT/EDIC are already in hand, and all methods for apolipoprotein subclass determination and for lipoprotein-cell interaction studies are established in our laboratories. The study brings together a unique population (DCCT/EDIC) with an important descriptor of lipoproteins never used in Type 1 diabetes, with the goal of preventing and treating complications
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pre-Eclampsia: Factors conferring Risk and Protectionn in Minority Women w/Dysgl
Pre-Eclampsia: Factors conferring Risk and Protectionn in Minority Women w/Dysgl
Lipoproteins and PEDF in the Vascular Complications of Diabetes
Lipoproteins and PEDF in the Vascular Complications of Diabetes
海外基金